Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Cybin announces receipt of its "may proceed letter" from the U.S. Food and Drug Administration (FDA) regarding its Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.
Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.
Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.
Optimi files an application with Health Canada to synthesize, process and produce pharmaceutical grade 3,4-Methylenedioxymethamphetamine ("MDMA").
Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.
Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.
Cybin Inc announces the submission of an Investigational New Drug application (IND) to the FDA for a Phase 1/2a clinical trial of CYB003 for major depressive disorder (MDD).
Optimi Health announces a new supply agreement with Filament Health to supply Filament with psilocybin mushrooms.
Novamind Inc reports its Q3 for fiscal 2022. Quarterly revenues of CAD$3,227,352 represent a q-o-q of 32%. Novamind also expanded into the Arizona market in Q2 with its clinic operations.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now